Construction of Pepstatin A-Conjugated ultrasmall SPIONs for targeted positive MR imaging of epilepsy-overexpressed P-glycoprotein

Du, Chengjuan; Wang, Jianhong; Liu, Xianping; Li, Huiming; Geng, Daoying; Yu, Luodan; Chen, Yu; Zhang, Jun

doi:10.1016/j.biomaterials.2019.119581

Cited by 24 publications

(22 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The NIR-II fluorescence intensities and MR T1WI signal intensities of different solutions [0.1 M PBS (pH 7.4), fetal bovine serum (FBS), and DMEM (Dulbecco's Modified Eagle Medium)] with the same concentration of Au-Gd NCs were evaluated. The NIR-II fluorescence intensities and MR T1WI signal intensities of Au-Gd NCs were computed with different values of pH (2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12).…”

Section: Stability Evaluationmentioning

confidence: 99%

“…The unique advantages of ultrasmall nanoprobes in biomedical applications are attributed to their good tumor permeability, improved pharmacokinetics, and effective in vivo metabolizability. [1][2][3][4][5][6] Gold nanoclusters (Au NCs), a kind of ultrasmall nanoprobe (size < 5.0 nm), have been exploited for near-infrared uorescence imaging and sensitization of radiotherapy owing to their quantum connement effect and high-Z elements. [7][8][9][10] Recent studies substantiate the extension of the uorescence emission of Au NCs from the rst near-infrared window (NIR-I, 650-950 nm) to the second near-infrared window (NIR-II, 1000-1700 nm) by optimization of reaction conditions and surface ligands.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Magnetic and near-infrared-II fluorescence Au–Gd nanoclusters for imaging-guided sensitization of tumor radiotherapy

Zhao

Wang

et al. 2022

Nanoscale Adv.

View full text Add to dashboard Cite

show abstract

Section: Stability Evaluationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Magnetic and near-infrared-II fluorescence Au–Gd nanoclusters for imaging-guided sensitization of tumor radiotherapy

Zhao

Wang

et al. 2022

Nanoscale Adv.

View full text Add to dashboard Cite

show abstract

“…To avoid the potential nephrotoxicity of Gd-based CAs, ultrasmall SPIONs have been explored as positive CAs. 42,43 The high surface area of these materials can facilitate the interaction of paramagnetic Fe 2+/3+ centers with water protons, thus enhancing relaxation. It is reported that a particle size of approximately 5 nm is optimal to offer a high r 1 and a small r 2 /r 1 ratio.…”

Section: T 1 -Mrimentioning

confidence: 99%

Theranostics for MRI‐guided therapy: Recent developments

Zhang

Zhou

Davies

et al. 2021

VIEW

View full text Add to dashboard Cite

Recent advances in bioimaging, biochemistry, and bioinformatics have facilitated the development of personalized and precision medicine. Theranostics, combining imaging modalities and therapeutic agents, have garnered a lot of attention in this context, owing to their potential to monitor and control treatment for individual patients. A promising strategy to achieve this goal involves the development of therapy guided by magnetic resonance imaging (MRI). MRI has a high degree of soft tissue contrast, low invasiveness, high depth of penetration and good spatial resolution. MRI‐guided therapy could thus allow precise and time‐resolved assessment of disease conditions and therapeutic progression. This article will give a brief introduction to the principles of MRI, and describe recently developed strategies to produce MRI‐guided therapies. A number of theranostics based on T1, T2, or chemical exchange saturation transfer (CEST) MRI have been explored to track the route of drug carriers in vivo and image diseased tissue so as to enhance bioavailability, overcome complex delivery barriers, and assess therapeutic responses. In addition, the integration of thermal therapy and MRI imaging offers a strategy to noninvasively identify target areas, plan treatment, and provide real‐time assessment of the efficacy of tumor ablation. We also discuss advances in intelligent nanoparticles combining small molecule drugs, thermal treatment and multimodal imaging, arguing that these multifunctional agents can further improve therapeutic outcomes.

show abstract

“…However, the performance of paramagnetic complexes based on gadolinium (Gd) is limited by rapid clearance from the blood into extravascular compartments, whereas T 2 contrast agents are nanosized and remain intravascular for a prolonged period of time. It should be noted that conventional T 1 MRI contrast agents based on metal oxides have a low relaxivity coefficient r 1 that decreases their sensitivity on T 1 -weighted MR images [ 24 , 25 , 26 , 27 , 28 ]. On the other hand, T 2 superparamagnetic contrast agents are associated with MR image distortion, and dark regions on T 2 -weighted images can easily be confused with other causes, such as calcification or metal deposits.…”

Section: Introductionmentioning

confidence: 99%

Theranostic Applications of an Ultra-Sensitive T1 and T2 Magnetic Resonance Contrast Agent Based on Cobalt Ferrite Spinel Nanoparticles

Mikhaylov

Mikac

Butinar

et al. 2022

Cancers

View full text Add to dashboard Cite

Nano-dimensional materials have become a focus of multiple clinical applications due to their unique physicochemical properties. Magnetic nanoparticles represent an important class of nanomaterials that are widely studied for use as magnetic resonance (MR) contrast and drug delivery agents, especially as they can be detected and manipulated remotely. Using magnetic cobalt ferrite spinel (MCFS) nanoparticles, this study was aimed at developing a multifunctional drug delivery platform with MRI capability for use in cancer treatment. We found that MCFS nanoparticles demonstrated outstanding properties for contrast MRI (r1 = 22.1 s–1mM–1 and r2 = 499 s–1mM–1) that enabled high-resolution T1- and T2-weighted MRI-based signal detection. Furthermore, MCFS nanoparticles were used for the development of a multifunctional targeted drug delivery platform for cancer treatment that is concurrently empowered with the MR contrast properties. Their therapeutic effect in systemic chemotherapy and unique MRI double-contrast properties were confirmed in vivo using a breast cancer mouse tumor model. Our study thus provides an empirical basis for the development of a novel multimodal composite drug delivery system for anticancer therapy combined with noninvasive MRI capability.

show abstract

Construction of Pepstatin A-Conjugated ultrasmall SPIONs for targeted positive MR imaging of epilepsy-overexpressed P-glycoprotein

Cited by 24 publications

References 50 publications

Magnetic and near-infrared-II fluorescence Au–Gd nanoclusters for imaging-guided sensitization of tumor radiotherapy

Magnetic and near-infrared-II fluorescence Au–Gd nanoclusters for imaging-guided sensitization of tumor radiotherapy

Theranostics for MRI‐guided therapy: Recent developments

Theranostic Applications of an Ultra-Sensitive T1 and T2 Magnetic Resonance Contrast Agent Based on Cobalt Ferrite Spinel Nanoparticles

Contact Info

Product

Resources

About